Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) vs GigCapital8 Corp. (GIW)

A side-by-side comparison of Drugs Made In America Acquisition Corp. Ordinary Shares and GigCapital8 Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DMAA vs GIW

growth of $100 · dividends reinvested · last 2y
DMAA +9.3% (+4.6%/yr)GIW -0.9% (-0.4%/yr)DMAA compounded faster over this window
100105110Start $1002026$109$99
DMAA GIW

DMAA vs GIW: by the numbers

  • •DMAA is the larger company ($264M vs $261M market cap).
  • •DMAA trades at the lower trailing earnings multiple (55.48 vs 67.71 P/E), one valuation lens rather than an overall verdict.

Metrics side by side

Valuation

MetricDMAAGIW
P/E ratio55.4867.71
P/B ratio1.921.00

Profitability

MetricDMAAGIW
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE4.42%1.17%
ROIC-1.82%-0.22%

Growth (annualized)

MetricDMAAGIW
Total return CAGR (5Y)N/A0.56%

Frequently asked

Which has the lower trailing P/E, DMAA or GIW?
DMAA has the lower trailing P/E: DMAA trades at 55.48 and GIW at 67.71. P/E is one valuation measure and does not by itself establish which business is cheaper.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.